Theravance Biopharma (TBPH) Short-term Investments (2014 - 2026)

Theravance Biopharma (TBPH) has 13 years of Short-term Investments data on file, last reported at $106.6 million in Q1 2026.

• Short-term Investments for Q1 2026 came in at $106.6 million, up 426.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $106.6 million (up 426.48% YoY), and the FY2025 annual result was $2.4 million, down 95.29% from the prior year.
• Short-term Investments grew to $106.6 million in Q1 2026 per TBPH's latest filing, from $2.4 million in the prior quarter.
• Over five years, Short-term Investments peaked at $106.6 million in Q1 2026 and troughed at $2.4 million in Q4 2025.
• A 5-year average of $49.4 million and a median of $53.1 million in 2022 frame the typical range for Short-term Investments.
• The sharpest annual moves came in 2025 and 2026: Short-term Investments plunged 96.49% in 2025, then jumped 426.48% in 2026.
• A 5-year view of Short-term Investments shows it stood at $29.3 million in 2022, then soared by 114.52% to $62.9 million in 2023, then dropped by 19.61% to $50.6 million in 2024, then tumbled by 95.29% to $2.4 million in 2025, then soared by 4375.64% to $106.6 million in 2026.
• Business Quant data shows TBPH's Short-term Investments at $106.6 million in Q1 2026, $2.4 million in Q4 2025, and $2.4 million in Q3 2025.